Chembio Diagnostics, Inc., together with its wholly-owned subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. The company was founded in 1985 and is based in Medford, New York.
Chembio Diagnostics (CEMI) +5.5% PM, initiated notification process and submission of an application for Emergency Use Authorization ((EUA)) to the U.S. FDA for its new rapid antibody test system, DPP SARS-CoV-2 IgM/IgG.The test system detects antibodies to the Spike Receptor Binding Domain in the blood that the body produces in response to a...
LOS ANGELES--(BUSINESS WIRE)---- $CEMI #classaction--The Law Offices of Frank R. Cruz reminds investors of the upcoming August 17, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Chembio Diagnostics, Inc. ("Chembio" or the "Company") (NASDAQ: CEMI) common stock between April 1, 2020 and June 16, 2020, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. In April 2020, the Company’s COVID-19 antibody test w
NEW YORK, NY / ACCESSWIRE / July 31, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below.